Cargando…

Microglial dysfunction as a key pathological change in adrenomyeloneuropathy

OBJECTIVE: Mutations in ABCD1 cause the neurodegenerative disease, adrenoleukodystrophy, which manifests as the spinal cord axonopathy adrenomyeloneuropathy (AMN) in nearly all males surviving into adulthood. Microglial dysfunction has long been implicated in pathogenesis of brain disease, but its r...

Descripción completa

Detalles Bibliográficos
Autores principales: Gong, Yi, Sasidharan, Nikhil, Laheji, Fiza, Frosch, Matthew, Musolino, Patricia, Tanzi, Rudy, Kim, Doo Yeon, Biffi, Alessandra, El Khoury, Joseph, Eichler, Florian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5725816/
https://www.ncbi.nlm.nih.gov/pubmed/29059709
http://dx.doi.org/10.1002/ana.25085
_version_ 1783285609107816448
author Gong, Yi
Sasidharan, Nikhil
Laheji, Fiza
Frosch, Matthew
Musolino, Patricia
Tanzi, Rudy
Kim, Doo Yeon
Biffi, Alessandra
El Khoury, Joseph
Eichler, Florian
author_facet Gong, Yi
Sasidharan, Nikhil
Laheji, Fiza
Frosch, Matthew
Musolino, Patricia
Tanzi, Rudy
Kim, Doo Yeon
Biffi, Alessandra
El Khoury, Joseph
Eichler, Florian
author_sort Gong, Yi
collection PubMed
description OBJECTIVE: Mutations in ABCD1 cause the neurodegenerative disease, adrenoleukodystrophy, which manifests as the spinal cord axonopathy adrenomyeloneuropathy (AMN) in nearly all males surviving into adulthood. Microglial dysfunction has long been implicated in pathogenesis of brain disease, but its role in the spinal cord is unclear. METHODS: We assessed spinal cord microglia in humans and mice with AMN and investigated the role of ABCD1 in microglial activity toward neuronal phagocytosis in cell culture. Because mutations in ABCD1 lead to incorporation of very‐long‐chain fatty acids into phospholipids, we separately examined the effects of lysophosphatidylcholine (LPC) upon microglia. RESULTS: Within the spinal cord of humans and mice with AMN, upregulation of several phagocytosis‐related markers, such as MFGE8 and TREM2, precedes complement activation and synapse loss. Unexpectedly, this occurs in the absence of overt inflammation. LPC C26:0 added to ABCD1‐deficient microglia in culture further enhances MFGE8 expression, aggravates phagocytosis, and leads to neuronal injury. Furthermore, exposure to a MFGE8‐blocking antibody reduces phagocytic activity. INTERPRETATION: Spinal cord microglia lacking ABCD1 are primed for phagocytosis, affecting neurons within an altered metabolic milieu. Blocking phagocytosis or specific phagocytic receptors may alleviate synapse loss and axonal degeneration. Ann Neurol 2017;82:813–827
format Online
Article
Text
id pubmed-5725816
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-57258162017-12-18 Microglial dysfunction as a key pathological change in adrenomyeloneuropathy Gong, Yi Sasidharan, Nikhil Laheji, Fiza Frosch, Matthew Musolino, Patricia Tanzi, Rudy Kim, Doo Yeon Biffi, Alessandra El Khoury, Joseph Eichler, Florian Ann Neurol Research Articles OBJECTIVE: Mutations in ABCD1 cause the neurodegenerative disease, adrenoleukodystrophy, which manifests as the spinal cord axonopathy adrenomyeloneuropathy (AMN) in nearly all males surviving into adulthood. Microglial dysfunction has long been implicated in pathogenesis of brain disease, but its role in the spinal cord is unclear. METHODS: We assessed spinal cord microglia in humans and mice with AMN and investigated the role of ABCD1 in microglial activity toward neuronal phagocytosis in cell culture. Because mutations in ABCD1 lead to incorporation of very‐long‐chain fatty acids into phospholipids, we separately examined the effects of lysophosphatidylcholine (LPC) upon microglia. RESULTS: Within the spinal cord of humans and mice with AMN, upregulation of several phagocytosis‐related markers, such as MFGE8 and TREM2, precedes complement activation and synapse loss. Unexpectedly, this occurs in the absence of overt inflammation. LPC C26:0 added to ABCD1‐deficient microglia in culture further enhances MFGE8 expression, aggravates phagocytosis, and leads to neuronal injury. Furthermore, exposure to a MFGE8‐blocking antibody reduces phagocytic activity. INTERPRETATION: Spinal cord microglia lacking ABCD1 are primed for phagocytosis, affecting neurons within an altered metabolic milieu. Blocking phagocytosis or specific phagocytic receptors may alleviate synapse loss and axonal degeneration. Ann Neurol 2017;82:813–827 John Wiley and Sons Inc. 2017-11-11 2017-11 /pmc/articles/PMC5725816/ /pubmed/29059709 http://dx.doi.org/10.1002/ana.25085 Text en © 2017 The Authors Annals of Neurology published by Wiley Periodicals, Inc. on behalf of American Neurological Association This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs (http://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Research Articles
Gong, Yi
Sasidharan, Nikhil
Laheji, Fiza
Frosch, Matthew
Musolino, Patricia
Tanzi, Rudy
Kim, Doo Yeon
Biffi, Alessandra
El Khoury, Joseph
Eichler, Florian
Microglial dysfunction as a key pathological change in adrenomyeloneuropathy
title Microglial dysfunction as a key pathological change in adrenomyeloneuropathy
title_full Microglial dysfunction as a key pathological change in adrenomyeloneuropathy
title_fullStr Microglial dysfunction as a key pathological change in adrenomyeloneuropathy
title_full_unstemmed Microglial dysfunction as a key pathological change in adrenomyeloneuropathy
title_short Microglial dysfunction as a key pathological change in adrenomyeloneuropathy
title_sort microglial dysfunction as a key pathological change in adrenomyeloneuropathy
topic Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5725816/
https://www.ncbi.nlm.nih.gov/pubmed/29059709
http://dx.doi.org/10.1002/ana.25085
work_keys_str_mv AT gongyi microglialdysfunctionasakeypathologicalchangeinadrenomyeloneuropathy
AT sasidharannikhil microglialdysfunctionasakeypathologicalchangeinadrenomyeloneuropathy
AT lahejifiza microglialdysfunctionasakeypathologicalchangeinadrenomyeloneuropathy
AT froschmatthew microglialdysfunctionasakeypathologicalchangeinadrenomyeloneuropathy
AT musolinopatricia microglialdysfunctionasakeypathologicalchangeinadrenomyeloneuropathy
AT tanzirudy microglialdysfunctionasakeypathologicalchangeinadrenomyeloneuropathy
AT kimdooyeon microglialdysfunctionasakeypathologicalchangeinadrenomyeloneuropathy
AT biffialessandra microglialdysfunctionasakeypathologicalchangeinadrenomyeloneuropathy
AT elkhouryjoseph microglialdysfunctionasakeypathologicalchangeinadrenomyeloneuropathy
AT eichlerflorian microglialdysfunctionasakeypathologicalchangeinadrenomyeloneuropathy